Media thread, page-1022

Based on the executive order described in the image—President Trump’s May 13, 2025 "favored nation" drug pricing mandate—it is highly unlikely that Orthocell (OCC) will be materially impacted, for the following reasons:

1. OCC Is Not a Pharmaceutical Company
• Scope of Order: This policy targets prescription drugs, specifically focusing on pharmaceutical medications reimbursed by U.S. healthcare programs like Medicare and Medicaid.
• OCC’s Products: Remplir and Striate are Class II/III medical devices, not pharmaceutical compounds. They are used in surgical procedures—nerve repair and dental bone regeneration—rather than dispensed like drugs.

2. Device-Based Reimbursement Pathways Are Excluded
• Medical devices like Remplir are regulated under CPT codes and device reimbursement frameworks, not under prescription drug formularies.
• The executive order doesn’t apply to surgical implants, biologic scaffolds, or regenerative matrix technologies, which are evaluated differently by insurers and Medicare.

3. OCC Pricing Is Not Inflated or Dependent on U.S.-Only Margins
• Most pharmaceutical MNCs rely on US market overpricing to subsidize low prices in Europe or Asia. That’s the core target of this order.
• OCC, by contrast, is new to market, with no history of inflated U.S. pricing. Its business model is scaling volume through multi-region launches—not squeezing margin from a single country.

4. Regulatory & Commercial Status Still in Launch Phase
• OCC hasn't even begun full-scale sales in the U.S. yet. It has approval, distributors, and pre-launch activity—but pricing discussions will likely happen directly with hospitals, surgeons, and private payers rather than Medicare first.
• If anything, OCC can bypass risk by leveraging specialist direct contracts in private surgical centers before entering public reimbursement systems.

5. Potential Indirect Tailwind (Mid-Term)
Here’s the counterintuitive possibility:
• If large drug companies are squeezed by this pricing order, it may accelerate M&A in adjacent markets like regenerative medicine, medical devices, and surgical solutions.
• Orthocell, with a strong moat in biologically regenerative devices, may look more attractive as acquirers shift focus from capped pharma revenues to next-gen surgical platforms.

Conclusion
OCC is not materially affected by this executive order.
• It’s not a pharma company.
• It’s not dependent on Medicare drug reimbursement.
• It’s not exposed to inflated US drug pricing corrections.

If anything, the pressure on pharma could increase strategic attention on OCC, particularly as a buyout target from MedTech majors diversifying away from drug revenue.